

- 3 -

Duggan *et al.*  
Appl. No. 09/529,130***Amendments to the Claims***

The listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-62 (canceled).

Claim 63 (currently amended). An agent for the treatment of pain, which comprises: a galactose-binding or an N-acetylgalactosamine-binding lectin; a light (L) chain or an L-chain fragment of a clostridial neurotoxin, which L-chain or L-chain fragment contains [[the]] a proteolytically active enzyme domain of the L-chain; and the translocation domain of a clostridial neurotoxin H-chain; wherein the L-chain or L-chain fragment and the translocation domain of the clostridial neurotoxin H-chain are linked by disulfide bond to form LH<sub>N</sub>, and wherein the LH<sub>N</sub> and the lectin are linked together by contacting the LH<sub>N</sub> and the lectin with one or more chemical coupling agents.

Claim 64 (canceled).

Claim 65 (previously presented). The agent according to Claim 63, wherein the lectin is of bacterial origin.

Claim 66 (previously presented). The agent according to Claim 65, wherein the lectin is obtained from *Pseudomonas aeruginosa*.

- 4 -

Duggan *et al.*  
Appl. No. 09/529,130

Claim 67-70 (canceled).

Claim 71. (previously presented)      The agent according to claim 63, wherein  
the LH<sub>N</sub> and the lectin are linked by SPDP.